NASDAQ:AIKI - AIkido Pharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $34.00
  • Forecasted Upside: 443.13 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$6.26
▲ +0.01 (0.16%)

This chart shows the closing price for AIKI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AIkido Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AIKI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AIKI

Analyst Price Target is $34.00
▲ +443.13% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for AIkido Pharma in the last 3 months. The average price target is $34.00, with a high forecast of $34.00 and a low forecast of $34.00. The average price target represents a 443.13% upside from the last price of $6.26.

This chart shows the closing price for AIKI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in AIkido Pharma.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/13/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/11/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/12/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/11/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/10/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/11/2021HC WainwrightInitiated CoverageBuy$34.00Low
(Data available from 8/10/2017 forward)

News Sentiment Rating

0.72 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/12/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/11/2022
  • 4 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
3/13/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/12/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/12/2022
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/11/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/10/2022

Current Sentiment

  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
AIkido Pharma logo
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.
Read More

Today's Range

Now: $6.26
Low: $6.26
High: $6.26

50 Day Range

MA: $5.77
Low: $4.65
High: $6.53

52 Week Range

Now: $6.26
Low: $4.30
High: $16.58

Volume

78 shs

Average Volume

86,059 shs

Market Capitalization

$32.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.37

Frequently Asked Questions

What sell-side analysts currently cover shares of AIkido Pharma?

The following Wall Street analysts have issued research reports on AIkido Pharma in the last year: HC Wainwright.
View the latest analyst ratings for AIKI.

What is the current price target for AIkido Pharma?

1 Wall Street analysts have set twelve-month price targets for AIkido Pharma in the last year. Their average twelve-month price target is $34.00, suggesting a possible upside of 443.1%. HC Wainwright has the highest price target set, predicting AIKI will reach $34.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $34.00 for AIkido Pharma in the next year.
View the latest price targets for AIKI.

What is the current consensus analyst rating for AIkido Pharma?

AIkido Pharma currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AIKI will outperform the market and that investors should add to their positions of AIkido Pharma.
View the latest ratings for AIKI.

What other companies compete with AIkido Pharma?

How do I contact AIkido Pharma's investor relations team?

AIkido Pharma's physical mailing address is ONE ROCKEFELLER PLAZA 11TH FLOOR, NEW YORK NY, 10020. The business services provider's listed phone number is (112) 745-1374 and its investor relations email address is [email protected] The official website for AIkido Pharma is www.spherix.com. Learn More about contacing AIkido Pharma investor relations.